BOT has demonstrated differentiated mechanisms to enhance T cell priming, activation, and memory to drive a more effective immune response and was intentionally designed to mitigate toxicities ...

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response ...

Labroots is pleased to announce the 5th annual event in the Immuno-Oncology Virtual Event Series taking place on April 29th, 2026. Immuno-Oncology is at the forefront of groundbreaking research in ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. Over the ...

Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next ...

Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the ...

International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN ...